Literature DB >> 492209

Serum creatine kinase and pyruvate kinase in Duchenne muscular dystrophy carrier detection.

M E Percy, L S Chang, E G Murphy, I Oss, C Verellen-Dumoulin, M W Thompson.   

Abstract

The incidence of elevated serum creatine kinase (CK) and pyruvate kinase (PK) activities was compared in 20 definite carriers of Duchenne muscular dystrophy (DMD), 47 possible carriers, and 42 female controls. When adult age was not regarded as a variable, 70% of the definite carriers had elevated PK, 55% had elevated CK, and 75% had elevated PK or elevated CK or both, 38% of the possible carriers had elevated PK, 19% had elevated CK, and 40% had elevated PK or elevated CK or both. The detection efficiency of the CK test was influenced by the age of the subjects: the upper normal limit of serum CK in the adult controls was at the minimum between 21 and 35 years of age, and CK activity in some carriers declined from elevated to normal levels with increasing age. With these considerations, 70% of definite carriers had elevated CK and 80% had elevated PK and/or CK; 34% of the possible carriers had elevated CK and 43% had elevated PK and/or CK. On the basis of the PK and CK measurements, only 16 of 24 possible carrier mothers were likely to be DMD carriers, implying that the other 8 were non-carrier mothers of new mutant sons.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 492209     DOI: 10.1002/mus.880020503

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Myoglobin is a sensitive marker of increased muscle membrane vulnerability.

Authors:  M F Driessen-Kletter; G J Amelink; P R Bär; J van Gijn
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

2.  Serum pyruvate kinase in different neuromuscular diseases and in carriers of muscular dystrophy.

Authors:  C Savonitto; G Bonadonna; L G Bongiovanni; E Duso; D De Grandis
Journal:  Ital J Neurol Sci       Date:  1983-12

Review 3.  Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention.

Authors:  H Moser
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

4.  The female carrier of Duchenne muscular dystrophy.

Authors:  V Dubowitz
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-15

5.  A method for the detection of carriers of Duchenne muscular dystrophy--a preliminary report.

Authors:  G Monckton; H Marusyk; E Pehowich
Journal:  Am J Hum Genet       Date:  1981-11       Impact factor: 11.025

6.  Precurarisation in infants and children less than three years of age.

Authors:  D A Cozanitis; O Erkola; U M Klemola; V Mäkelä
Journal:  Can J Anaesth       Date:  1987-01       Impact factor: 5.063

7.  Detection of carriers for Duchenne muscular dystrophy. Quality control of creatine kinase assay.

Authors:  H Plauchu; C Junien; I Maire; R Said; R Gozlan; J M Lalouel
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

8.  Results of blind testing a method to detect carriers of the Duchenne muscular dystrophy gene.

Authors:  G Monckton; M Zatz; C S Mion; H Marusyk
Journal:  Am J Hum Genet       Date:  1984-07       Impact factor: 11.025

9.  The dystrophic murine skeletal muscle cell plasma membrane is structurally intact but "leaky" to creatine phosphokinase. A freeze-fracture analysis.

Authors:  R R Shivers; B G Atkinson
Journal:  Am J Pathol       Date:  1984-09       Impact factor: 4.307

10.  A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice.

Authors:  Kazuhiro Kobuke; Federica Piccolo; Keith W Garringer; Steven A Moore; Eileen Sweezer; Baoli Yang; Kevin P Campbell
Journal:  Hum Mol Genet       Date:  2008-02-05       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.